Annual Review of Genomics and Human Genetics This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The < em > Myriad < /em > Decision at 10
Annu Rev Genomics Hum Genet. 2024 Feb 29. doi: 10.1146/annurev-genom-010323-011239. Online ahead of print.ABSTRACTA decade ago, the US Supreme Court decided Association for Molecular Pathology v. Myriad Genetics, Inc., concluding that isolated genes were not patentable subject matter. Beyond being a mere patent dispute, the case was a political and cultural phenomenon, viewed as a harbinger for the health of the biotechnology industry. With a decade of perspective, though, Myriad's impact seems much narrower. The law surrounding patentable subject matter-while greatly transformed-only centered on Myriad in small part. The ...
Source: Annual Review of Genomics and Human Genetics - February 29, 2024 Category: Genetics & Stem Cells Authors: Jacob S Sherkow Robert Cook-Deegan Henry T Greely Source Type: research

The < em > Myriad < /em > Decision at 10
Annu Rev Genomics Hum Genet. 2024 Feb 29. doi: 10.1146/annurev-genom-010323-011239. Online ahead of print.ABSTRACTA decade ago, the US Supreme Court decided Association for Molecular Pathology v. Myriad Genetics, Inc., concluding that isolated genes were not patentable subject matter. Beyond being a mere patent dispute, the case was a political and cultural phenomenon, viewed as a harbinger for the health of the biotechnology industry. With a decade of perspective, though, Myriad's impact seems much narrower. The law surrounding patentable subject matter-while greatly transformed-only centered on Myriad in small part. The ...
Source: Annual Review of Genomics and Human Genetics - February 29, 2024 Category: Genetics & Stem Cells Authors: Jacob S Sherkow Robert Cook-Deegan Henry T Greely Source Type: research

The < em > Myriad < /em > Decision at 10
Annu Rev Genomics Hum Genet. 2024 Feb 29. doi: 10.1146/annurev-genom-010323-011239. Online ahead of print.ABSTRACTA decade ago, the US Supreme Court decided Association for Molecular Pathology v. Myriad Genetics, Inc., concluding that isolated genes were not patentable subject matter. Beyond being a mere patent dispute, the case was a political and cultural phenomenon, viewed as a harbinger for the health of the biotechnology industry. With a decade of perspective, though, Myriad's impact seems much narrower. The law surrounding patentable subject matter-while greatly transformed-only centered on Myriad in small part. The ...
Source: Annual Review of Genomics and Human Genetics - February 29, 2024 Category: Genetics & Stem Cells Authors: Jacob S Sherkow Robert Cook-Deegan Henry T Greely Source Type: research

The < em > Myriad < /em > Decision at 10
Annu Rev Genomics Hum Genet. 2024 Feb 29. doi: 10.1146/annurev-genom-010323-011239. Online ahead of print.ABSTRACTA decade ago, the US Supreme Court decided Association for Molecular Pathology v. Myriad Genetics, Inc., concluding that isolated genes were not patentable subject matter. Beyond being a mere patent dispute, the case was a political and cultural phenomenon, viewed as a harbinger for the health of the biotechnology industry. With a decade of perspective, though, Myriad's impact seems much narrower. The law surrounding patentable subject matter-while greatly transformed-only centered on Myriad in small part. The ...
Source: Annual Review of Genomics and Human Genetics - February 29, 2024 Category: Genetics & Stem Cells Authors: Jacob S Sherkow Robert Cook-Deegan Henry T Greely Source Type: research

The < em > Myriad < /em > Decision at 10
Annu Rev Genomics Hum Genet. 2024 Feb 29. doi: 10.1146/annurev-genom-010323-011239. Online ahead of print.ABSTRACTA decade ago, the US Supreme Court decided Association for Molecular Pathology v. Myriad Genetics, Inc., concluding that isolated genes were not patentable subject matter. Beyond being a mere patent dispute, the case was a political and cultural phenomenon, viewed as a harbinger for the health of the biotechnology industry. With a decade of perspective, though, Myriad's impact seems much narrower. The law surrounding patentable subject matter-while greatly transformed-only centered on Myriad in small part. The ...
Source: Annual Review of Genomics and Human Genetics - February 29, 2024 Category: Genetics & Stem Cells Authors: Jacob S Sherkow Robert Cook-Deegan Henry T Greely Source Type: research

The < em > Myriad < /em > Decision at 10
Annu Rev Genomics Hum Genet. 2024 Feb 29. doi: 10.1146/annurev-genom-010323-011239. Online ahead of print.ABSTRACTA decade ago, the US Supreme Court decided Association for Molecular Pathology v. Myriad Genetics, Inc., concluding that isolated genes were not patentable subject matter. Beyond being a mere patent dispute, the case was a political and cultural phenomenon, viewed as a harbinger for the health of the biotechnology industry. With a decade of perspective, though, Myriad's impact seems much narrower. The law surrounding patentable subject matter-while greatly transformed-only centered on Myriad in small part. The ...
Source: Annual Review of Genomics and Human Genetics - February 29, 2024 Category: Genetics & Stem Cells Authors: Jacob S Sherkow Robert Cook-Deegan Henry T Greely Source Type: research

The < em > Myriad < /em > Decision at 10
Annu Rev Genomics Hum Genet. 2024 Feb 29. doi: 10.1146/annurev-genom-010323-011239. Online ahead of print.ABSTRACTA decade ago, the US Supreme Court decided Association for Molecular Pathology v. Myriad Genetics, Inc., concluding that isolated genes were not patentable subject matter. Beyond being a mere patent dispute, the case was a political and cultural phenomenon, viewed as a harbinger for the health of the biotechnology industry. With a decade of perspective, though, Myriad's impact seems much narrower. The law surrounding patentable subject matter-while greatly transformed-only centered on Myriad in small part. The ...
Source: Annual Review of Genomics and Human Genetics - February 29, 2024 Category: Genetics & Stem Cells Authors: Jacob S Sherkow Robert Cook-Deegan Henry T Greely Source Type: research

The < em > Myriad < /em > Decision at 10
Annu Rev Genomics Hum Genet. 2024 Feb 29. doi: 10.1146/annurev-genom-010323-011239. Online ahead of print.ABSTRACTA decade ago, the US Supreme Court decided Association for Molecular Pathology v. Myriad Genetics, Inc., concluding that isolated genes were not patentable subject matter. Beyond being a mere patent dispute, the case was a political and cultural phenomenon, viewed as a harbinger for the health of the biotechnology industry. With a decade of perspective, though, Myriad's impact seems much narrower. The law surrounding patentable subject matter-while greatly transformed-only centered on Myriad in small part. The ...
Source: Annual Review of Genomics and Human Genetics - February 29, 2024 Category: Genetics & Stem Cells Authors: Jacob S Sherkow Robert Cook-Deegan Henry T Greely Source Type: research

The < em > Myriad < /em > Decision at 10
Annu Rev Genomics Hum Genet. 2024 Feb 29. doi: 10.1146/annurev-genom-010323-011239. Online ahead of print.ABSTRACTA decade ago, the US Supreme Court decided Association for Molecular Pathology v. Myriad Genetics, Inc., concluding that isolated genes were not patentable subject matter. Beyond being a mere patent dispute, the case was a political and cultural phenomenon, viewed as a harbinger for the health of the biotechnology industry. With a decade of perspective, though, Myriad's impact seems much narrower. The law surrounding patentable subject matter-while greatly transformed-only centered on Myriad in small part. The ...
Source: Annual Review of Genomics and Human Genetics - February 29, 2024 Category: Genetics & Stem Cells Authors: Jacob S Sherkow Robert Cook-Deegan Henry T Greely Source Type: research

The < em > Myriad < /em > Decision at 10
Annu Rev Genomics Hum Genet. 2024 Feb 29. doi: 10.1146/annurev-genom-010323-011239. Online ahead of print.ABSTRACTA decade ago, the US Supreme Court decided Association for Molecular Pathology v. Myriad Genetics, Inc., concluding that isolated genes were not patentable subject matter. Beyond being a mere patent dispute, the case was a political and cultural phenomenon, viewed as a harbinger for the health of the biotechnology industry. With a decade of perspective, though, Myriad's impact seems much narrower. The law surrounding patentable subject matter-while greatly transformed-only centered on Myriad in small part. The ...
Source: Annual Review of Genomics and Human Genetics - February 29, 2024 Category: Genetics & Stem Cells Authors: Jacob S Sherkow Robert Cook-Deegan Henry T Greely Source Type: research

The < em > Myriad < /em > Decision at 10
Annu Rev Genomics Hum Genet. 2024 Feb 29. doi: 10.1146/annurev-genom-010323-011239. Online ahead of print.ABSTRACTA decade ago, the US Supreme Court decided Association for Molecular Pathology v. Myriad Genetics, Inc., concluding that isolated genes were not patentable subject matter. Beyond being a mere patent dispute, the case was a political and cultural phenomenon, viewed as a harbinger for the health of the biotechnology industry. With a decade of perspective, though, Myriad's impact seems much narrower. The law surrounding patentable subject matter-while greatly transformed-only centered on Myriad in small part. The ...
Source: Annual Review of Genomics and Human Genetics - February 29, 2024 Category: Genetics & Stem Cells Authors: Jacob S Sherkow Robert Cook-Deegan Henry T Greely Source Type: research

The < em > Myriad < /em > Decision at 10
Annu Rev Genomics Hum Genet. 2024 Feb 29. doi: 10.1146/annurev-genom-010323-011239. Online ahead of print.ABSTRACTA decade ago, the US Supreme Court decided Association for Molecular Pathology v. Myriad Genetics, Inc., concluding that isolated genes were not patentable subject matter. Beyond being a mere patent dispute, the case was a political and cultural phenomenon, viewed as a harbinger for the health of the biotechnology industry. With a decade of perspective, though, Myriad's impact seems much narrower. The law surrounding patentable subject matter-while greatly transformed-only centered on Myriad in small part. The ...
Source: Annual Review of Genomics and Human Genetics - February 29, 2024 Category: Genetics & Stem Cells Authors: Jacob S Sherkow Robert Cook-Deegan Henry T Greely Source Type: research

The < em > Myriad < /em > Decision at 10
Annu Rev Genomics Hum Genet. 2024 Feb 29. doi: 10.1146/annurev-genom-010323-011239. Online ahead of print.ABSTRACTA decade ago, the US Supreme Court decided Association for Molecular Pathology v. Myriad Genetics, Inc., concluding that isolated genes were not patentable subject matter. Beyond being a mere patent dispute, the case was a political and cultural phenomenon, viewed as a harbinger for the health of the biotechnology industry. With a decade of perspective, though, Myriad's impact seems much narrower. The law surrounding patentable subject matter-while greatly transformed-only centered on Myriad in small part. The ...
Source: Annual Review of Genomics and Human Genetics - February 29, 2024 Category: Genetics & Stem Cells Authors: Jacob S Sherkow Robert Cook-Deegan Henry T Greely Source Type: research

The < em > Myriad < /em > Decision at 10
Annu Rev Genomics Hum Genet. 2024 Feb 29. doi: 10.1146/annurev-genom-010323-011239. Online ahead of print.ABSTRACTA decade ago, the US Supreme Court decided Association for Molecular Pathology v. Myriad Genetics, Inc., concluding that isolated genes were not patentable subject matter. Beyond being a mere patent dispute, the case was a political and cultural phenomenon, viewed as a harbinger for the health of the biotechnology industry. With a decade of perspective, though, Myriad's impact seems much narrower. The law surrounding patentable subject matter-while greatly transformed-only centered on Myriad in small part. The ...
Source: Annual Review of Genomics and Human Genetics - February 29, 2024 Category: Genetics & Stem Cells Authors: Jacob S Sherkow Robert Cook-Deegan Henry T Greely Source Type: research

The < em > Myriad < /em > Decision at 10
Annu Rev Genomics Hum Genet. 2024 Feb 29. doi: 10.1146/annurev-genom-010323-011239. Online ahead of print.ABSTRACTA decade ago, the US Supreme Court decided Association for Molecular Pathology v. Myriad Genetics, Inc., concluding that isolated genes were not patentable subject matter. Beyond being a mere patent dispute, the case was a political and cultural phenomenon, viewed as a harbinger for the health of the biotechnology industry. With a decade of perspective, though, Myriad's impact seems much narrower. The law surrounding patentable subject matter-while greatly transformed-only centered on Myriad in small part. The ...
Source: Annual Review of Genomics and Human Genetics - February 29, 2024 Category: Genetics & Stem Cells Authors: Jacob S Sherkow Robert Cook-Deegan Henry T Greely Source Type: research